Acurx Pharmaceuticals Inc
Company Profile
Business description
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
Contact
259 Liberty Avenue
Staten IslandNY10305
USAT: +1 917 533-1469
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
4
Stocks News & Analysis
stocks
SpaceX: What investors need to know about its enormous upcoming IPO
stocks
Fair value lifts for toll road operator as Aussie fuel supply steadies
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,966.00 | 17.10 | 0.19% |
| CAC 40 | 8,182.03 | 35.44 | 0.44% |
| DAX 40 | 25,110.49 | 107.45 | 0.43% |
| Dow JONES (US) | 51,173.94 | 95.06 | 0.19% |
| FTSE 100 | 10,353.96 | 15.01 | 0.15% |
| HKSE | 26,038.32 | 640.14 | 2.52% |
| NASDAQ | 27,000.41 | 86.40 | -0.32% |
| Nikkei 225 | 66,734.24 | 200.09 | -0.30% |
| NZX 50 Index | 13,170.71 | 73.84 | -0.56% |
| S&P 500 | 7,591.28 | 8.68 | -0.11% |
| S&P/ASX 200 | 8,724.40 | 17.70 | 0.20% |
| SSE Composite Index | 4,075.10 | 17.36 | 0.43% |